Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With<i>ERBB2</i>Amplification or<i>ERBB2/3</i>Mutations: Results From the TAPUR Study - Concepedia

Concepedia

Publication | Closed Access

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With<i>ERBB2</i>Amplification or<i>ERBB2/3</i>Mutations: Results From the TAPUR Study

57

Citations

24

References

2022

Year

R. Gupta, Funda Meric‐Bernstam, Michael Rothe, Elizabeth Garrett‐Mayer, Pam K. Mangat, Stacy D. D’Andre, Eugene R. Ahn, Raegan O'Lone, Susan Halabi, Gina N. Grantham,

JCO Precision Oncology

Abstract

Although P + T treatment does not appear to have antitumor activity in CRC with <i>ERBB2/3</i> mutations, this combination has antitumor activity in patients with CRC with <i>ERBB2</i> amplification and warrants further study.

References

	Year	Citations

Page 1